DNAnexus provides a cloud-based biomedical data analysis platform that enables researchers and life sciences companies to analyze genomic, transcriptomic, proteomic, metabolomic, and clinical datasets together. The company powers large-scale initiatives — it built and supports the UK Biobank Research Analysis Platform and exclusively partnered with the FDA to power precisionFDA. DNAnexus reports more than 12,000 platform users across 48 countries, stores over 65 petabytes of data, and says its stored data has grown 70% per year since 2015. Its customer base includes seven of the top 10 pharmaceutical companies and eight of the top 10 diagnostics companies. The company will use new funding to accelerate its product roadmap, advance its core genomics and multi-omics platform, expand internationally, and support integration of new AI and machine-learning technologies to drive precision medicine. DNAnexus offers an enterprise-grade, cloud-native informatics platform that simplifies complex data analysis, clinical data management, and insights at population scale. The DNAnexus Platform combines genomics, multi-omics, and real-world data with clinical datasets to support diagnostics, drug discovery, and cross-institutional collaboration. Customers run 10 million core processing hours per month and now store 28 petabytes of data, a dataset that has grown roughly 70% per year over the past four years. Its customer base spans government, biopharmaceutical, clinical diagnostics, healthcare, and academic research across 33 countries and includes eight of the top 10 clinical diagnostics companies and seven of the top 10 pharmaceutical companies. The platform supports some of the largest human genome sequencing projects and powers FDA’s precisionFDA platform. DNAnexus reports continued customer growth during the COVID-19 pandemic as organizations adopted its virtual cloud workspace. The company says the financing will advance its global expansion and further development of its data science and scaling capabilities. DNAnexus provides a secure, scalable platform for managing and analyzing genomics and other biomedical data. Its Apollo platform enables multi-omics and clinical data exploration, analysis, and discovery across the DNAnexus global network. The company operates in 33 countries, serving thousands of researchers across biopharmaceutical, bioagricultural, sequencing services, clinical diagnostics, government, and research consortia. DNAnexus supports major projects including NIH’s All of Us, St. Jude Cloud, AstraZeneca’s 2‑million genome initiative, and the Regeneron‑Geisinger collaboration. The firm offers cloud-based solutions for research, clinical diagnostics, and clinical trials and emphasizes cross-institutional collaboration on large biomedical datasets. The recent financing is positioned to support further development of translational research solutions and continued growth in genomics. DNAnexus provides a secure, scalable cloud platform that enables enterprises and research organizations to manage, analyze and share large genomic and biomedical datasets. The company offers products including the DNAnexus Platform and the recently launched Mosaic Microbiome Platform, and has an early access program for Google Brain’s DeepVariant technology. It is developing and preparing to deploy a Translational Informatics Suite aimed at pharmaceutical and research customers. DNAnexus serves thousands of researchers across biopharma, clinical diagnostics, sequencing services, government and research consortia, and operates globally across North America, Europe, Asia‑Pacific (including China), South America and Africa. The company has announced collaborations with AstraZeneca’s Centre for Genomics Research and Rady Children’s Institute for Genomic Medicine. Recent financing will support expansion in the clinical trials market and continued product development and deployment. DNAnexus provides an enterprise PaaS that centralizes management, analysis, and sharing of DNA sequence data for labs and large organizations. The platform supplies secure, compliant cloud infrastructure that supports unlimited scaling of computational and storage resources and meets HIPAA, CLIA, and international regulatory requirements. It serves as a hub for collaboration, tool sharing, and access to reference genotypic and phenotypic datasets. Through projects with Stanford University and Baylor College of Medicine, DNAnexus processed over 17,000 genomes and generated more than 500 terabytes of genomic data, making those datasets available for follow-on analysis. The company reports rapid customer adoption and plans to expand capacity to support growing commercial and academic lab usage. DNAnexus has closed a $15 million Series C to accelerate commercialization of its enterprise platform.

Total raised

$458M

Funding rounds

8

Latest round

Equity

Latest activity

Mar 2022